End-to-end safety platform spanning intake, ICSR processing, signals, aggregate reporting, and submissions.

覆盖摄入、ICSR 处理、信号、汇总报告与递交的端到端安全平台。

AI: AI：Most explicitly 'agentic' positioning in the market — NavaX Agents for MedDRA coding, signal management, and regulatory intelligence.市场上最明确的「agentic」定位——NavaX Agents 负责 MedDRA 编码、信号管理与监管情报。

• Deep PV-specific heritage — built the first commercial drug-safety system
• Broadest 'agentic AI' roadmap in the category (NavaX Agents)
• Regulator adoption (FDA / Health Canada / NMPA) as users

• 深厚的 PV 专长——打造了首个商用药物安全系统
• 品类内最广的「agentic AI」路线图（NavaX Agents）
• 监管机构（FDA / Health Canada / NMPA）作为用户背书

• Single-domain — less of a unified clinical-to-commercial platform than Veeva/Oracle
• Legacy-modernization perception around the core MultiVigilance suite
• Ownership / headcount opacity makes scale hard to verify

• 聚焦单一领域——不如 Veeva / Oracle 那样的临床到商业一体化平台
• 核心 MultiVigilance 套件存在「老系统翻新」的外界印象
• 所有权 / 人数不透明，规模难以核实

Customers: FDA, Health Canada, NMPA, 220+ life-sciences orgs & CROs

客户：FDA、Health Canada、NMPA、220+ 家生命科学机构与 CRO

Recent: Early-2026 launches: ReporterX, NavaX Translation, and the XDI data-intelligence platform; a top-10 pharma selected NavaX-powered Advanced Intake + Literature Intelligence.

近期：2026 年初推出 ReporterX、NavaX Translation 与 XDI 数据智能平台；一家前十大药企选用 NavaX 驱动的高级摄入与文献情报。

Long-standing category leader: Argus for case management/E2B, Empirica for statistical signal data-mining.

长期的品类领导者：Argus 负责病例管理 / E2B，Empirica 负责统计信号数据挖掘。

AI: AI：AI-assisted case processing and signal detection layered onto the established Argus + Empirica duo.在成熟的 Argus + Empirica 组合上叠加 AI 辅助病例处理与信号检测。

• Argus is the de-facto enterprise ICSR standard — huge installed base
• Empirica is a mature statistical signal-detection / data-mining engine
• Enterprise scale, global database coverage (incl. JADER)

• Argus 是事实上的企业级 ICSR 标准——装机量巨大
• Empirica 是成熟的统计信号检测 / 数据挖掘引擎
• 企业级规模，全球数据库覆盖（含 JADER）

• Legacy architecture / UX vs. cloud-native rivals
• Integration and upgrade complexity and cost
• Slower AI-agent narrative than Veeva / ArisGlobal

• 相较云原生对手，架构 / 体验偏老旧
• 集成与升级复杂、成本高
• AI 智能体叙事推进慢于 Veeva / ArisGlobal

Customers: Large global pharma (names not disclosed)

客户：大型全球药企（未披露具体名称）

Recent: Continued Argus Cloud Service (R8.4.1) and Empirica out-of-the-box global-database expansions; AI-assisted case processing layered onto the existing suite.

近期：持续推进 Argus 云服务（R8.4.1）与 Empirica 开箱即用的全球数据库扩展；在既有套件上叠加 AI 辅助病例处理。

Unified case intake-to-submission with built-in E2B gateway and automated dictionary updates; connected to clinical/quality/regulatory Vaults.

从病例摄入到递交一体化，内置 E2B 网关与自动词典更新；与临床 / 质量 / 监管 Vault 互联。

AI: AI：Case Intake Agent (auto extraction + anomaly detection) and Case Narrative Agent (narrative drafting).Case Intake Agent（自动抽取 + 异常检测）与 Case Narrative Agent（叙述初稿生成）。

• Modern cloud-native UX, three regulatory releases per year
• Seamless clinical→safety data integration via Veeva Connections
• Strong platform momentum across the Vault ecosystem

• 现代云原生体验，每年三个监管版本
• 通过 Veeva Connections 实现临床→安全数据无缝集成
• 依托 Vault 生态的强劲平台势能

• Newer / less mature in PV than Argus — smaller safety installed base
• Best value realized inside the Veeva ecosystem; weaker for non-Veeva shops
• Signal-management depth still maturing

• PV 领域较 Argus 更新、更不成熟——安全装机量较小
• 价值主要在 Veeva 生态内释放；对非 Veeva 客户吸引力较弱
• 信号管理深度仍在完善中

Customers: UCB, LEO Pharma, CRISPR Therapeutics, Merck, Biomapas

客户：UCB、LEO Pharma、CRISPR Therapeutics、默克、Biomapas

Recent: Veeva AI for Safety: Case Intake Agent (extraction + anomaly detection) and Case Narrative Agent (narrative drafting) — positioning a shift from reactive PV to proactive 'safety intelligence'.

近期：Veeva AI for Safety：Case Intake Agent（抽取 + 异常检测）与 Case Narrative Agent（叙述生成）——定位从被动 PV 转向主动的「安全智能」。

Modular SaaS across the PV lifecycle plus large PV BPO/managed services.

覆盖 PV 全生命周期的模块化 SaaS，外加大型 PV BPO / 托管服务。

AI: AI：Vigilance Detect uses AI/NLP to identify AEs across social + audio in 50+ languages; GenAI for near-'touchless' case processing.Vigilance Detect 用 AI/NLP 在 50+ 语言的社媒与音频中识别 AE；GenAI 实现近乎「零接触」病例处理。

• Unmatched real-world data assets (~1.2B patient records) feeding analytics
• Full bundle: PV tech + BPO managed services + CRO
• Global scale across 100+ countries

• 无可比拟的真实世界数据资产（约 12 亿患者记录）支撑分析
• 全套打包：PV 技术 + BPO 托管服务 + CRO
• 覆盖 100+ 国家的全球规模

• PV is a small slice of a sprawling conglomerate — less focused than pure-plays
• Potential lock-in / conflict concerns when bundling tech with consulting
• Cost

• PV 只是庞大集团中的一小块——不如纯 PV 厂商专注
• 技术与咨询打包销售存在潜在锁定 / 利益冲突顾虑
• 成本较高

Customers: Broad pharma & biotech base (PV-specific names not disclosed)

客户：广泛的药企与生物科技客户（PV 具体名称未披露）

Recent: Vigilance Detect adds GenAI/ML + NLP adverse-event detection across email, audio, docs and chat; vendor claims ~80% fewer false positives and ~50% cost reduction.

近期：Vigilance Detect 增加 GenAI/ML + NLP，在邮件、音频、文档与聊天中检测 AE；厂商称误报减少约 80%、成本降低约 50%。

Conference case study: 'One System, One Truth' — end-to-end integration of safety surveillance.

会议案例：「一套系统，一个真相」——安全监测的端到端整合。

AI: AI：Integration-led narrative; AI/automation positioned around unifying surveillance data.以整合为主线；AI / 自动化定位于统一监测数据。

• Broad end-to-end PV module coverage on one platform ('Safety-In-A-Box')
• Deep top-pharma + regulator footprint (9 of top-10 pharma)
• Profitable / self-funded — no investor pressure

• 单平台上的广泛端到端 PV 模块覆盖（「Safety-In-A-Box」）
• 深厚的头部药企 + 监管机构客户基础（前十大药企占九）
• 盈利 / 自筹——无投资人压力

• Inconsistent public corporate data (even HQ varies across sources)
• Bootstrapped means slower capital to scale vs. PE-backed rivals
• AI claims (80%/50%) are vendor-stated, no independent validation

• 公开公司信息不一致（连总部在各来源都不同）
• 自筹资金意味着扩张资本慢于 PE 背景对手
• AI 主张（80%/50%）为厂商自述，无独立验证

Customers: 45+ pharma orgs incl. 9 of top-10 global pharma, FDA, EMA

客户：45+ 家药企，含前十大全球药企中的 9 家、FDA、EMA

Recent: Launched PVOne.AI, a 'fourth-generation' agentic-AI PV platform (claims 80% manual-work reduction, 50% fewer false positives); active at DIA Europe 2025 and its own PV Innovation Conference (Tokyo).

近期：推出 PVOne.AI——「第四代」agentic-AI PV 平台（称减少 80% 人工、误报降低 50%）；活跃于 DIA Europe 2025 及自办的 PV 创新大会（东京）。

Conference case study: 'Reimagining Pharmacovigilance: Human-AI Interactive Intelligence.'

会议案例：「重塑药物警戒：人机交互智能」。

AI: AI：AI-native, human-in-the-loop framing aligned with CIOMS WG XIV 'augment not replace' principle.AI 原生、人在回路的定位，契合 CIOMS WG XIV「增强而非替代」原则。

• AI-native architecture built from the ground up
• Pharma parent (Daewoong) as domain anchor and proving ground
• Freshly funded Series A for core tech + global expansion

• 从零构建的 AI 原生架构
• 药企母公司（大熊）作为领域锚点与试验场
• 刚完成 A 轮，用于核心技术与全球扩张

• Tiny scale (~16 staff)
• Early-stage with limited customer proof outside the parent
• Korea-centric — minimal global track record

• 规模极小（约 16 人）
• 早期阶段，母公司之外的客户验证有限
• 以韩国为中心——全球业绩记录极少

Customers: Daewoong Pharmaceutical (parent / anchor)

客户：大熊制药（母公司 / 锚定用户）

Recent: Closed a KRW 9.2B (~$6.8M) Series A in Jan 2025 (KB Investment, Korea Investment Partners, Yuanta, SJ Investment Partners, Genaxis) to build core tech and expand globally.

近期：2025 年 1 月完成 92 亿韩元（约 680 万美元）A 轮（KB Investment、韩投伙伴、元大、SJ Investment Partners、Genaxis），用于核心技术与全球扩张。

Conference case study: global PV and risk-management system setup, acquisition-support to strategic partnership.

会议案例：全球 PV 与风险管理系统搭建，从并购支持到战略合作。

AI: AI：Services-led; technology + AI deployed within managed PV operations.以服务为主导；在托管 PV 运营中部署技术 + AI。

• Large, medically-staffed global services scale (100+ physicians, 90% HCP staff)
• Broad breadth: PV + medical info + regulatory affairs + medical writing + QA
• AE reporting across 100+ countries with a multi-region inspection track record

• 大型、以医学人员为主的全球服务规模（100+ 名医师，90% 为医疗专业人员）
• 覆盖广：PV + 医学信息 + 法规事务 + 医学撰写 + 质量保证
• 在 100+ 国家进行 AE 报告，具备多地区检查记录

• Services / BPO-dependent — people-heavy, not a scalable software product
• Little proprietary-AI / platform differentiation disclosed
• No named marquee customers

• 依赖服务 / BPO——人力密集，非可规模化的软件产品
• 公开的自有 AI / 平台差异化很少
• 无具名标杆客户

Customers: Named customers not disclosed (testimonials only)

客户：未披露具名客户（仅有客户评价）

Recent: Active on the conference circuit (DIA Global Annual Meeting 2025, booth #1124); positioning remains services-led rather than product-AI-led.

近期：活跃于各大会议（DIA 2025 年会，展位 #1124）；定位仍以服务为主，而非产品化 AI。

Conference case study: operational challenges and safety strategies for combination products.

会议案例：组合产品的运营挑战与安全策略。

AI: AI：Domain-specialist services; limited public AI positioning.领域专长服务；公开的 AI 定位有限。

• Niche combination drug-device product risk-management expertise
• Full-service CRO breadth (clinical ops, regulatory, PV, medical writing, QMS)
• India cost base

• 组合药械产品风险管理的细分专长
• 全服务 CRO 广度（临床运营、法规、PV、医学撰写、QMS）
• 印度成本优势

• Very small (~79 staff); minimal public footprint
• Broad-CRO positioning dilutes the combination-product specialism
• Largely services — no productized PV software

• 规模很小（约 79 人）；公开信息极少
• 宽泛的 CRO 定位稀释了组合产品的专长
• 以服务为主——无产品化 PV 软件

Customers: Not disclosed

客户：未披露

Recent: Presented a DIA session 'Decode the Risk Management for Combination Products'; otherwise a very thin public record.

近期：在 DIA 做了「解码组合产品风险管理」的分享；除此之外公开记录非常有限。